Refine by
Renal Injury Articles & Analysis
29 news found
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. Diabetes mellitus, a chronic condition characterized by elevated blood ...
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
ByBayer AG
XARENO is the first prospective observational study to evaluate the effectiveness and safety of a NOAC versus VKAs in treating patients with NVAF and advanced CKD (estimated glomerular filtration rates (eGFR) of 15-49 mL/min/1.73 m2). Avoiding worsening renal function is an important clinical consideration beyond stroke prevention when it comes to the selection of an oral ...
ByBayer AG
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study FIGARO-DKD included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD ...
ByBayer AG
SeqOne today announced the results of a long-standing research collaboration with Pr. Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving the diagnosis and management of patients suspected of suffering from thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS). The program involved using Oxford Nanopore’s ...
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive in-hospital and 30-day outcomes from the fully-enrolled 500-patient CLOUT registry. The company also reported positive results from a propensity-matched comparison of patients ...
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- Alnylam ...
MatTek Life Sciences will distribute Cell4Pharma’s ciPTEC renal cells and utilize the technology in the development of a new in vitro kidney model. ...
These data show that INV-202, the company’s lead peripheral CB1 blocker, reduced renal injury in a murine model of Streptozotocin (STZ)-induced Diabetes. More specifically, INV-202 reduced glomerular injury, renal fibrosis and injury to proximal tubular epithelial cells, and also preserved podocyte ...
Globally there are 3.5 million patients who are solely dependent on renal replacement therapy to preserve life. These figures are increasing due to rising incidence of chronic kidney disease, diabetes and acute kidney injury. ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. This is the second year of this unique program aimed at eliminating barriers to care for ...
Like many people with atrial fibrillation (AFib), Sheldon Kittelson of Clarkfield, Minnesota, felt trapped between the fear of having a stroke and the fear of spending a lifetime on blood thinners. For people with AFib, blood doesn’t flow through the heart normally, which can result in a clot forming in the left atrial appendage (LAA) that can break loose and lead to a stroke. ...
Kerendia is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) The approval is based on the results of the Phase III FIDELIO-DKD study investigating the efficacy and safety of Kerendia on kidney and CV outcomes in ...
ByBayer AG
Xavier Badia, MD, MPH, PhD of Omakase Consulting S.L. presented the poster titled “Epidemiology and Clinical Management of Patients with Methotrexate Toxicity in Spain Using the Delphi Technique,” which shows that 11.6% of patients in Spain treated with HDMTX can be expected to develop acute kidney injury, with mortality estimated in 4.2% of cases. These results are ...
The Accuryn Monitoring System includes a revolutionary sensor-integrated foley catheter that provides real-time, actionable information to healthcare providers, enabling them to take important, earlier steps to prevent disease state progression of critical conditions such as acute kidney injury (AKI). The app is available exclusively on the Accuryn Monitoring System and will be ...
Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio (UACR) with ...
ByBayer AG
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced results of the PHYOX™2 pivotal clinical trial of nedosiran, an investigational GalXC™ RNAi candidate for the treatment of primary hyperoxaluria (PH), in a late-breaker poster presentation at the American Society of Nephrology (ASN) ...
Potrero Medical, innovator of the Accuryn Monitoring System, a sensory integrated foley catheter that provides real-time, actionable information to health care providers so they can take steps to prevent the progression of critical conditions such as acute kidney injury (AKI), announced that Steve Okland will join Potrero Medical as Chief Commercial Officer. “We are excited to welcome Steve ...
Potrero Medical, innovator of the Accuryn Monitoring System, a sensory integrated foley catheter that provides real-time, actionable information to health care providers so they can take steps to prevent the progression of critical conditions such as acute kidney injury (AKI), announced that Rebecca Lin has been promoted to the role of Chief Strategic Officer. “As we prepare the company ...
Procedure removes risk of kidney injury or complications in patients with advanced kidney disease or allergy to contrast dye On Sept. 30, CentraCare completed the world’s first contrast-free WATCHMAN implant using 4D holographic therapy guidance, developed by EchoPixel, as the alternative imaging modality. Rather than relying on contrast dye and X-ray based imaging to help guide the ...